A general history of England.

Planned to extend to 1660, but not completed beyond 1654.

The visitation of the county of Warwick, begun by Thomas May, Chester, and Gregory King, Rouge dragon, in Hilary vacacōn, 1682. Reviewed by them in the Trinity vacacōn following, and finished by Henry Dethick Richmond, and said rouge dragon pursuiv in Trinity vacation, 1683, by virtue of several deputations from Sir Henry St. George, Clarenceux king of arms.

Report of the society for the year 1910 (3 p.) appended.

A descriptive catalogue (with remarks and anecdotes never before published in English) of some pictures, of the different schools, purchased for His Majesty the late King of Poland, which will be exhibited early in 1802, at the Great Room, No. 3, in Berners-Street, the third door on the right, from Oxford-Street /

Mode of access: Internet.

Leges marchiarum, or, border-laws : containing several original articles and treaties, made and agreed upon by the commissioners of the respective kings of England and Scotland : for the better preservation of peace and commerce upon the marches of both kingdoms : from the reign of Henry III. to the union of the two crowns in K. James I : with a preface, and an appendix of charters and records, relating to the said treaties /

Signatures : A¹², a⁶, B-M¹².

Chronicles of England, France, Spain, and the adjoining countries, from the latter part of the reign of Edward II to the coronation of Henri IV /

The life of the author, essay on his works, and criticism on his history are translated from the French of Jean Baptiste de La Curne de Sainte-Palaye.

A new history of England from the descent of the Romans to the demise of this late majesty, George II; inscribed to his present majesty, George III;

Vols. 47-50 continue the history to 1763.

The Political history of England.

Reprint of the 1905-14 ed.

Rogeri de Wendover Liber qui dicitur Flores historiarum ab Anno Domini MCLIV. annoque Henrici Anglorum regis secundi primo. The flowers of history by Roger de Wendover: from the year of Our Lord 1154, and the first year of Henry the Second, king of the English.

"The present edition is confined to that portion of Wendover's chronicle which comprises the materials ... collected by himself" [i.e. 1154-1235]--Pref., v. 1.

Chronicles of the reigns of Stephen, Henry II., and Richard I.

Vol. 4 has imprint: London, Printed for H. M. Stationery off., by Eyre and Spottiswoode.

Caroline, the illustrious queen-consort of George II. and sometime queen-regent; a study of her life and time,

"A list of authorities": p. 627-29.

History of Great Britain, from the death of Henry VIII. to the accession of James VI. of Scotland to the crown of England. Being a continuation of Dr. Henry's history of Great Britain, and written on the same plan.

On spine: v. 13 and 14. Continues Robert Henry's History of Great Britain.

The history of England.

A summary of the history of Engalnd, from the invasion of Julius Caesar to the death of George I: 274 p. at end of v. 4.

Oath of allegiance to George II by Jews in American colonies

Digital image

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer

AIMS: The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients.

PATIENTS & METHODS: Patients were randomized to receive nintedanib (250 mg twice daily), afatinib (40 mg once daily [q.d.]), or alternating sequential 7-day nintedanib (250 mg twice daily) and afatinib (70 mg q.d. [Combi70]), which was reduced to 40 mg q.d. (Combi40) due to adverse events. The primary end point was progression-free rate at 12 weeks.

RESULTS: Of the 85 patients treated 46, 20, 16 and three received nintedanib, afatinib, Combi40 and Combi70, respectively. At 12 weeks, the progression-free rate was 26% (seven out of 27 patients) for nintedanib, and 0% for afatinib and Combi40 groups. Two patients had a ≥50% decline in PSA (nintedanib and the Combi40 groups). The most common drug-related adverse events were diarrhea, nausea, vomiting and lethargy.

CONCLUSION: Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients.